Fate Therapeutics jumps in debut

Fate Therapeutics (FATE +13%) opens at $6.56 and moves sharply higher.

The offering priced at the low-end of its expected range, notable because the company had already lowered the range to $6-8 from $14-16.

FATE's lead product is ProHema, a hematopoietic stem cell therapeutic derived from umbilical cord blood.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs